A Relative Bioavailability Study of Danoprevir and Ritonavir in Healthy Volunteers

Inclusion criteria

• Healthy volunteers, 18 to 45 years of age inclusive
• Body mass index 18.0 - 32.0 kg/m2, weight >/= 50 kg
• Healthy status will be defined as absence of evidence of any active or chronic disease following a detailed medical and surgical history and a complete physical examination
• Non-smoker
• Medical history without major, recent or ongoing pathology
• Females of childbearing potential and males and their female partners of childbearing potential must agree to use 2 forms of contraception (barrier form plus intrauterine device and spemicide) during the study and for 90 days after the last drug administration

Exclusion criteria

• Pregnant or lactating women or males with female partners who are pregnant or lactating
• Positive results for drugs of abuse at screening or prior to admission to the clinical site during any study period
• Positive for hepatitis B, hepatitis C or HIV infection
• Use of hormonal contraceptives (birth control pills, injectable, implantable devices) within 30 days before the first dose of study medication
• Routine use of more than 2 g of acetaminophen daily
• History of clinically significant drug allergy (such as anaphylaxis) or hepatotoxicity
• History of hypersensitivity to danoptevir, ritonavir, or other protease inhibitors
• History (within 3 months of screening) of alcohol consumption exceeding 2 standard drinks per day on average
• Current enrollment or participation in a clinical trial of an experimental medication or medical device within 3 months of screening unless agreed upon by the Sponsor